Core Insights - The company reported a slight increase in revenue for Q3 2025, with a total of 1.084 billion yuan, representing a year-on-year growth of 0.10% [1] - However, the net profit attributable to shareholders saw a significant decline of 48.47%, amounting to 75.422 million yuan [1] - For the first three quarters of 2025, the company achieved a revenue of 3.184 billion yuan, reflecting a year-on-year growth of 1.88%, while the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [1] Revenue Analysis - Q3 2025 revenue reached 1.084 billion yuan, showing a marginal increase compared to the previous year [1] - Year-to-date revenue for the first three quarters totaled 3.184 billion yuan, indicating a modest growth of 1.88% [1] Profitability Overview - The net profit for Q3 2025 was 75.422 million yuan, down 48.47% year-on-year [1] - The net profit for the first three quarters was 203 million yuan, which is a decline of 33.91% compared to the same period last year [1] Key Factors Impacting Performance - The decline in net profit is primarily attributed to the previous year's asset disposal gains from the acquisition of state-owned land use rights and properties, which contributed approximately 93 million yuan to the net profit in the same period last year [1]

证券代码：603301 证券简称：振德医疗 公告编号：2025-039 振德医疗用品股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2025 年 11 月 13 日（星期四）10:00-11:00 2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星 期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明 会上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告。为便于广大投资者更全 面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划 于 2025 年 11 月 1 ...

Financial Performance - Total revenue for the third quarter was ¥1,084,062,685.61, representing a year-on-year increase of 0.10%[4] - Total profit decreased by 49.85% to ¥91,769,976.45 compared to the same period last year[4] - Net profit attributable to shareholders was ¥75,421,982.51, down 48.47% year-on-year[4] - Basic and diluted earnings per share both decreased by 49.09% to ¥0.28[5] - The weighted average return on equity decreased by 1.33 percentage points to 1.33%[5] - Net profit for the first three quarters of 2025 was ¥210,543,772.08, down from ¥317,474,354.86 in 2024, reflecting a decrease of approximately 33.6%[22] - Basic earnings per share for the first three quarters of 2025 were ¥0.76, down from ¥1.15 in the same period of 2024, representing a decline of approximately 33.9%[22] Assets and Liabilities - Total assets increased by 10.92% to ¥8,404,612,469.65 compared to the end of the previous year[5] - The company's total assets increased to ¥8,404,612,469.65 in 2025 from ¥7,576,854,384.35 in 2024, marking a growth of about 10.9%[17] - Total liabilities rose to ¥2,419,250,212.67 in 2025, compared to ¥1,680,456,463.01 in 2024, an increase of approximately 43.9%[17] - The company's total non-current assets amounted to ¥5,486,517,555.15 in 2025, up from ¥4,927,035,342.48 in 2024, indicating a growth of about 11.4%[17] Cash Flow - Net cash flow from operating activities for the year-to-date was ¥262,639,201.32, an increase of 64.65%[4][10] - Operating cash flow for the first three quarters of 2025 reached ¥262,639,201.32, a 64.5% increase from ¥159,518,116.70 in the same period of 2024[25] - Total cash inflow from operating activities was ¥3,695,211,630.06, compared to ¥3,382,595,024.60 in 2024, reflecting an increase of 9.2%[25] - Cash outflow for purchasing goods and services was ¥2,047,025,563.82, up from ¥1,991,557,515.14 in 2024, indicating a rise of 2.8%[25] - Cash inflow from financing activities increased to ¥1,536,500,000.00, compared to ¥1,419,260,000.00 in the previous year, marking an 8.3% growth[26] - Net cash flow from financing activities was ¥619,687,236.34, significantly higher than ¥234,402,342.05 in 2024, representing a 164.5% increase[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,562[12] - Zhejiang Zhendé Holdings Co., Ltd. holds 49.82% of the shares, with 132,739,480 shares pledged[12] - The company has a total of 13,322,560 shares (5.00% of total shares) to be transferred at a price of RMB 26.74 per share, totaling RMB 356,245,254.40[14] - The company has no significant changes in the top ten shareholders participating in margin financing and securities lending[13] - The company’s major shareholders include both corporate and individual entities, with no known related party transactions among them[13] Inventory and Receivables - Accounts receivable stand at RMB 693,903,555.27, down from RMB 756,695,009.51[15] - Inventory is reported at RMB 762,281,766.54, slightly decreased from RMB 770,721,810.80[15] - Total current assets amount to RMB 2,918,094,914.50, compared to RMB 2,649,819,041.87 in the previous period[15] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥99,515,975.55, slightly up from ¥98,872,971.89 in 2024, reflecting a marginal increase of about 0.6%[21] Non-Recurring Items - Non-recurring gains and losses for the current period totaled ¥10,587,609.54[8] - The decrease in total profit and net profit was primarily due to asset disposal gains from the previous year, which were not repeated this year[9][10]

Core Viewpoint - On October 28, 2025, Zhendemedical (603301) closed at 80.95 yuan, reaching the daily limit with a 10.0% increase, indicating strong market interest and trading activity [1][2]. Trading Information Summary - The stock hit the daily limit at 9:45 AM, with a total of 8 instances of the limit being opened during the trading day, and the final closing order amount was 49.1451 million yuan, accounting for 0.23% of its circulating market value [1][2]. - On the same day, the net inflow of main funds was 62.9061 million yuan, representing 4.91% of the total transaction amount, while speculative funds experienced a net outflow of 106 million yuan, which was 8.28% of the total transaction amount [1][2]. - Retail investors saw a net inflow of 43.1042 million yuan, making up 3.37% of the total transaction amount [1][2].

Market Overview - On October 28, the medical device sector rose by 0.21%, led by Chutian Technology, while the Shanghai Composite Index closed at 3988.22, down 0.22%, and the Shenzhen Component Index closed at 13430.1, down 0.44% [1]. Top Performers - Chutian Technology (300358) closed at 11.32, with a significant increase of 20.04% and a trading volume of 842,800 shares, amounting to a transaction value of 924 million yuan [1]. - Libang Instruments (300206) saw a closing price of 13.97, up 15.45%, with a trading volume of 521,600 shares and a transaction value of 718 million yuan [1]. - Zhend Medical (603301) closed at 80.95, increasing by 10.00%, with a trading volume of 159,900 shares [1]. Underperformers - Sino Medical (688108) experienced a decline of 9.39%, closing at 25.19, with a trading volume of 415,300 shares and a transaction value of 1.084 billion yuan [2]. - Yingke Medical (300677) closed at 38.56, down 8.58%, with a trading volume of 333,700 shares [2]. - Nanwei Medical (688029) saw a decrease of 6.30%, closing at 81.52, with a trading volume of 56,100 shares [2]. Capital Flow - The medical device sector experienced a net outflow of 405 million yuan from institutional investors, while retail investors saw a net inflow of 417 million yuan [2][3]. - Chutian Technology had a net inflow of 162.16 million yuan from institutional investors, while retail investors had a net outflow of 64.44 million yuan [3]. - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are actively buying [2][3].

Market Overview - The Shanghai Composite Index rose by 0.22% on October 23, with 21 out of 28 sectors experiencing gains. The top-performing sectors were coal and oil & petrochemicals, with increases of 1.75% and 1.53% respectively. Conversely, the telecommunications and real estate sectors saw declines of 1.51% and 0.99% respectively [1] Capital Flow Analysis - The main capital flow showed a net outflow of 33.733 billion yuan across the two markets. Six sectors experienced net inflows, with the coal sector leading at a net inflow of 1.465 billion yuan, followed by the media sector with a net inflow of 362 million yuan [1] - A total of 25 sectors faced net outflows, with the electronics sector experiencing the largest outflow of 5.435 billion yuan, followed by the machinery equipment sector with an outflow of 4.999 billion yuan. Other sectors with significant outflows included pharmaceuticals, telecommunications, and electrical equipment [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector declined by 0.60%, with a net outflow of 4.627 billion yuan. Out of 475 stocks in this sector, 183 stocks rose, 4 stocks hit the daily limit up, and 274 stocks fell [2] - Within the sector, 121 stocks saw net inflows, with five stocks receiving over 30 million yuan in net inflows. The top stock for net inflow was Jianfa Zhixin, with an inflow of 123 million yuan, followed by Sainuo Medical and Mindray Medical with inflows of 121 million yuan and 60.069 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jianfa Zhixin: +20.00% with a turnover rate of 59.71% and a net inflow of 122.929 million yuan - Sainuo Medical: +4.74% with a turnover rate of 6.99% and a net inflow of 121.228 million yuan - Mindray Medical: +0.73% with a turnover rate of 0.41% and a net inflow of 60.069 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Shutaishen: -7.52% with a net outflow of 195.891 million yuan - Zhendai Medical: +2.51% with a net outflow of 185.422 million yuan - Yatai Pharmaceutical: -5.58% with a net outflow of 164.905 million yuan [3]

Core Insights - The "Second Golden Unicorn Best Investment Advisor Selection" event is currently ongoing, with over 3,000 professional investment advisors participating in simulated trading competitions aimed at enhancing the wealth management industry in China [1]. Group 1: Top Stocks by Purchase Frequency - The top ten stocks purchased by frequency on October 23 are led by Jifeng Co., Ltd. (stock code: sh603997) and include notable companies such as XWANDA (sz300207) and Agricultural Bank of China (sh601288) [1]. Group 2: Top Stocks by Purchase Amount - The top ten stocks by purchase amount on October 23 include Three Gorges New Materials (sh600293) and Guangku Technology (sz300620), with significant investments also seen in companies like Bright Real Estate (sh600708) and Shenghong Technology (sz300476) [2]. Group 3: Event Structure and Data Explanation - The event features a competitive evaluation of investment capabilities across three categories: stock simulation group, on-market ETF simulation group, and public fund simulation configuration group, with specific trading rules regarding holding proportions, maximum drawdown rates, and rebalancing frequency [4]. - The data presented reflects simulated trading activities and is not indicative of actual trading scenarios, serving solely as a reference [4].

Core Viewpoint - Zhendé Medical has shown significant stock price appreciation in 2023, with a year-to-date increase of 244.61% and notable recent trading activity, indicating strong market interest and potential investment opportunities [1][2]. Group 1: Stock Performance - As of October 23, Zhendé Medical's stock price reached 73.54 CNY per share, with a market capitalization of 19.595 billion CNY [1]. - The stock has experienced a 2.01% increase during the trading session on October 23, with a trading volume of 2.10 billion CNY and a turnover rate of 1.08% [1]. - Year-to-date, the stock has risen by 244.61%, with recent increases of 8.90% over the last five trading days, 86.89% over the last 20 days, and 236.26% over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Zhendé Medical reported revenue of 2.1 billion CNY, reflecting a year-on-year growth of 2.83%, while net profit attributable to shareholders decreased by 20.70% to 128 million CNY [2]. - The company's main revenue sources include surgical infection control (43.04%), basic care (20.46%), ostomy and modern wound care (18.59%), pressure treatment and fixation (10.75%), infection control protection (6.58%), and others (0.58%) [2]. Group 3: Shareholder Information - As of June 30, 2025, Zhendé Medical had 22,600 shareholders, a decrease of 8.29% from the previous period, with an average of 11,767 circulating shares per shareholder, an increase of 9.04% [2]. - The company has distributed a total of 1.46 billion CNY in dividends since its A-share listing, with 706 million CNY distributed over the past three years [3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.7482 million shares, an increase of 80,700 shares from the previous period, while the招商核心竞争力混合A fund holds 3.4286 million shares, an increase of 58.10% [3].

Core Viewpoint - Zhendemedical has shown significant stock price appreciation in 2023, with a year-to-date increase of 239.03% and notable recent trading activity, indicating strong investor interest and market performance [2][3]. Stock Performance - As of October 22, Zhendemedical's stock price reached 72.35 CNY per share, with a trading volume of 4.75 billion CNY and a market capitalization of 19.278 billion CNY [1]. - The stock has experienced a 239.03% increase year-to-date, an 11.57% increase over the last five trading days, and an 85.51% increase over the last 20 days [2]. Trading Activity - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) three times this year, with the latest instance on October 13, where it recorded a net buy of 41.3766 million CNY [2]. - The total buying amount on that day was 225 million CNY, accounting for 23.61% of total trading volume, while total selling was 184 million CNY, making up 19.28% [2]. Company Overview - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, is located in Shaoxing, Zhejiang Province, and specializes in the production, research, and sales of medical dressings [2]. - The company's revenue composition includes: 43.04% from surgical infection control, 20.46% from basic care, 18.59% from ostomy and modern wound care, 10.75% from pressure treatment and fixation, 6.58% from infection control protection, and 0.58% from other sources [2]. Financial Performance - For the first half of 2025, Zhendemedical reported a revenue of 2.1 billion CNY, reflecting a year-on-year growth of 2.83%, while the net profit attributable to shareholders was 128 million CNY, down 20.70% year-on-year [3]. - The company has distributed a total of 1.46 billion CNY in dividends since its A-share listing, with 706 million CNY distributed over the past three years [4]. Shareholder Information - As of June 30, 2025, the number of shareholders was 22,600, a decrease of 8.29% from the previous period, with an average of 11,767 shares held per shareholder, an increase of 9.04% [3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.7482 million shares, an increase of 80,700 shares from the previous period, while the招商核心竞争力混合A fund holds 3.4286 million shares, an increase of 581,000 shares [4].

New Stock Offerings - The offer period for the acquisition of Shangwei New Materials (688585) is from September 29, 2025, to October 28, 2025[1] - The latest announcements for various stocks include BoRui Pharmaceutical (688166) and Nanxin Pharmaceutical (688189) on October 10, 2025[1] - Significant abnormal fluctuations were reported for Nanxin Pharmaceutical (688189) on October 10, 2025[1] Trading Alerts - A total of 30 stocks have trading alerts issued on October 20, 2025, including Anlikang (002940) and ST Baoying (002047)[1] - The trading alerts cover various sectors, indicating potential volatility in the market[1] - The latest announcements for stocks such as YD Holdings (000626) and ST Nanzhi (002305) were made on October 20, 2025[1]